PepGen Inc. PEPG
4.61 USD +2.22 (+92.89%)
At closeNov 10, 2026, 7:59 PM EST
5.18 +0.57 +12.36%
After hours · Nov 10, 7:59 PM ET
4.42 Day range 6.44
1.31 52-week range 7.80
- YTD
- -29.19%
- 1 year
- +8.22%
News
seekingalpha.com PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results Transcript PepGen Inc. ( PEPG ) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results November 10, 2026 8:00 AM EST Company Participants James McArthur - President, CEO, Treasurer, Secretary &…
benzinga.com PepGen Commences $125M Common Stock Offering PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the…
businesswire.com PepGen Announces Proposed $125.0 Million Public Offering of Common Stock BOSTON--(BUSINESS WIRE)--PepGen Announces Proposed $125.0 Million Public Offering of Common Stock.
benzinga.com PepGen Stock Doubles in One Session - Here's Why PepGen Inc. (NASDAQ:PEPG) stock surged on Tuesday with a strong session Volume of 31.855 million, compared to an average volume of 983.011 thousand, according to Benzinga Pro data.
benzinga.com PepGen Stock Doubles in One Session - Here's Why PepGen reports positive Phase 2 results for PGN-EDODM1 in DM1, showing record splicing correction and notable functional improvements.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imaging
benzinga.com Gold Down 2%; TransDigm Group Posts Upbeat Earnings U.S. stocks fell Tuesday, led by tech; Dow dropped 300+ points. TransDigm beat estimates, while PepGen surged 142% and Microvast plunged 64%.
benzinga.com Nasdaq Down Over 200 Points; US Consumer Prices Increase 0.4% In October U.S. stocks fell as October CPI topped expectations; energy led losses. Oil and gold declined, while European and Asian markets advanced.
benzinga.com PepGen Q3 EPS $(0.28) Misses $(0.27) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 46.15 percent increase over losses of $(0.52) per…
benzinga.com PepGen Announces Data From Its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 Demonstrates Mean Splicing Correction Of 46.5%; PGN-EDODM1 Showed High Tolerance; PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced…
businesswire.com PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights.
businesswire.com PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results.
defenseworld.net PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts PepGen, Inc. (NASDAQ: PEPG - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat reports. One analyst has…
defenseworld.net PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC Squarepoint Ops LLC raised its holdings in PepGen, Inc. (NASDAQ: PEPG) by 260.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
benzinga.com HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target HC Wainwright & Co. analyst Ananda Ghosh reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $20 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
defenseworld.net ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG ADAR1 Capital Management LLC acquired a new position in PepGen, Inc. (NASDAQ: PEPG) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm…
benzinga.com PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per…
gurufocus.com PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights [url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran
gurufocus.com PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the- benzinga.com PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into…
businesswire.com PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.
businesswire.com PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.- benzinga.com Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11 Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $11.
benzinga.com PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15 PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…
businesswire.com PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of…
zacks.com PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates…- benzinga.com PepGen Files For $400M Shelf Registration And $100M At-The-Market Stock Offering https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm
zacks.com PepGen (PEPG) Upgraded to Buy: Here's What You Should Know PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).- benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $4 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $5 to $4.
benzinga.com PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 71.74 percent increase over losses of $(0.92) per…
businesswire.com PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to…
benzinga.com Top 3 Health Care Stocks Which Could Blast Off This Quarter Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)
benzinga.com Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on top names. For a complete view of all rating changes, see analyst ratings page.- benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $9 to $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.2%, while utilities fall 0.7%. FactSet reports upbeat Q2 results and raises outlook.- benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $9 to $5.
benzinga.com Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell 0.6%. TD Synnex beats earnings estimates.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Is PepGen Stock Sinking Tuesday? PepGen stock drops after Phase 2 low-dose data show limited splicing correction; higher-dose cohorts and FDA hold remain key focus areas.
benzinga.com Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its second SpaceShip is expected to enter service soon, causing a 6% jump in pre-market trading. Other…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com PepGen Announces Clinical Data From The 5 Mg/Kg Multiple Ascending Dose Cohort Of The Ongoing Phase 2 FREEDOM2-DM1 Trial In Patients With Myotonic Dystrophy Type 1; PGN-EDOM1 Was Generally Well-Tolerated With All Adverse Events Mild Or Moderate And No Serious Adverse Events Reported PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…
benzinga.com Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down.